We are live on
!
Find out more
Lineage Cell Therapeutics
LCTX
LCTX
124 hedge funds and large institutions have $182M invested in Lineage Cell Therapeutics in 2021 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 27 increasing their positions, 39 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
457% more call options, than puts
Call options by funds: $1.61M | Put options by funds: $289K
56% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 16
8% more funds holding
Funds holding: 115 → 124 (+9)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.15% less ownership
Funds ownership: 45.28% → 44.13% (-1.2%)
5% less capital invested
Capital invested by funds: $192M → $182M (-$9.95M)
31% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 39
Holders
124
Holders Change
+9
Holders Change %
+7.83%
% of All Funds
1.91%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
25
Increased
27
Reduced
39
Closed
16
Calls
$1.61M
Puts
$289K
Net Calls
+$1.32M
Net Calls Change
+$448K
Top Buyers
| 1 |
BlackRock
New York
|
+$3.41M |
| 2 |
RA
Raffles Associates
New York
|
+$1.05M |
| 3 |
Morgan Stanley
New York
|
+$944K |
| 4 |
Millennium Management
New York
|
+$734K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$714K |
Top Sellers
| 1 |
State Street
Boston,
Massachusetts
|
-$7.92M |
| 2 |
JP Morgan Chase
New York
|
-$2.18M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$975K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$913K |
| 5 |
Rafferty Asset Management
New York
|
-$488K |
